Recursion Pharmaceuticals Stock

recursionpharma.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $333.7MM

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

Register for Details

For more details on financing and valuation for Recursion Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Recursion Pharmaceuticals.

Register Today

Team

Management Team

Mason Victors
Chief Technology Officer & Chief Product Officer
Sharath Hegde
Chief Scientific Officer
Ronald Alfa Ph.D
Senior Vice President of Translational Discovery & Chief Evangelist
Blake Borgeson Ph.D
Co-Founder, Scientific Advisor & Board Member
Christopher Gibson Ph.D
Co-Founder, Chief Executive Officer & Board Member
Kevin Leggat
Controller
Kevin Lynch Ph.D
Chief Business Officer
Dean Li Ph.D
Board Member & Founder
Tina Larson
Chief Operating Officer
Ben Sukow
Director, Engineering
Heather Kirkby
Chief People Officer

Board Members

Blake Borgeson Ph.D
Zavain Dar
Lux Capital Management
Alaa Halawa
Mubadala Investment Company
Dean Li Ph.D
Zachary Bogue JD
Data Collective
Nan Li
Obvious Ventures
Christopher Gibson Ph.D
Reid Hutchins
Advantage Capital (Saint Louis)
Perry Fell Ph.D
James Hardiman
Data Collective

Other companies like Recursion Pharmaceuticals in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Recursion Gets Funding For New Drug Discovery With Bayer-led $239M Series D
The new investment provides Recursion with capital to further develop its drug discovery platform and pipeline.
Recursion : Appoints Heather Kirkby as Chief People Officer
Updated on: Sep 28, 2023